Pharmaceuticals company RPG Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations: Rs 143.09 crore up from Rs 126.99 crore, Up by 13% YoY. PBT before exceptional items: Rs 25.00 crore up from Rs 17.74 crore, Surges 41% YoY. FY25 Financial Highlights: Revenue from operations: Rs 653.43 crore up from Rs 582.05 crore, Up by 12% YoY. PBT before exceptional items: 150.28 crore up from Rs 117.84 crore, Surges 28% YoY. EBITDA Margin Expanding from 23.3% to 26.4% YoY. Yugal Sikri, Managing Director, RPG Life Sciences, said: “In Q4FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 13% and 41% respectively YoY. The full year EBITDA margin surged from 23.3% to 26.4% YoY, retaining its upward trajectory YoY for the last 6 years. Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets. We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D; units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth. Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted YoY margin expansion trajectory. The Company has built sizeable cash surplus of ~Rs 168 crore from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to ~Rs 266 crore. We are actively pursuing inorganic opportunities to accelerate business growth. On the back of continued robust performance, The Board of Directors has recommended highest ever dividend of 250% plus a special dividend of 50% on the face value of Rs 8 each for FY25, subject to the approval of shareholders at the ensuing Annual General Meeting, thus maintaining an upward trajectory of dividend for the last 6 years.” Result PDF